yes i take peptides · shopping companion

Cerebrolysin

Category · For CognitionStatus · RXCitations · 60

The verdict

Mostly no — Cerebrolysin has approval in ~50 countries and a substantial Eastern European clinical tradition for stroke, TBI, and dementia, but the strongest Western evidence (Cochrane 2020) shows no mortality benefit in stroke plus a signal of increased serious adverse events, and the US import-restricted RUO supply chain is a separate problem on top of the efficacy picture.

By source — cost, legality, risk

Brand — Cerebrolysin (Ever Pharma, 50+ countries)
$120–$220/course at EU retail (US import restricted)
Rx in EU/Asia · NOT FDA-approved in US · import legally restricted (biologic)
Real product. Most-trialed peptide in this batch but not legally available to US patients.
Compounded 503A pharmacy
Not available
Not compoundable — porcine brain hydrolysate biologic
503A pharmacies cannot synthesize undefined biologic mixtures; brand or medical tourism are the only legitimate channels.
RUO research peptide
Rarely sold; identity unverifiable
Sold 'for research only' · molecular identity essentially unverifiable
Highest. The brand is a defined manufacturing process, not a single molecule — 'RUO Cerebrolysin' is functionally a different product.
Gray-market raw
Varies — not on user's vendor list
Unregulated overseas import
Gray-market peptide vendors do not carry biologics. Practical cheap path is medical tourism (real product, EU/Asian clinic), not raw powder.

Sources · top 5 of 60

01Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2023;10(10):CD007026. PMID: 37818733.
02Cui S, et al. Cerebrolysin for vascular dementia. The Cochrane database of systematic reviews. 2019;2019(11). PMID: 31710397.
03Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2020;7(7):CD007026. PMID: 32662068.
04Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2017;4(4):CD007026. PMID: 28430363.
05Brainin M. Cerebrolysin: a multi-target drug for recovery after stroke. Expert review of neurotherapeutics. 2018;18(8):681-687. PMID: 30004268.